International Country-Level Trends, Factors, and Disparities in Compassionate Use Access to Unlicensed Products for Patients With Serious Medical Conditions
Author:
Affiliation:
1. Novartis Pharma AG, Basel, Switzerland
2. GE2P2 Global Foundation, Philadelphia, Pennsylvania
3. Novartis Healthcare Pvt Ltd, Hyderabad, India
4. Novartis Pharmaceuticals Corporation, East Hanover, New Jersey
Publisher
American Medical Association (AMA)
Subject
General Earth and Planetary Sciences,General Environmental Science
Link
https://jamanetwork.com/journals/jama-health-forum/articlepdf/2791197/aliu_2022_oi_220013_1649870792.08109.pdf
Reference47 articles.
1. Little to lose and no other options: ethical issues in efforts to facilitate expanded access to investigational drugs.;Bunnik;Health Policy,2018
2. Early access programs: benefits, challenges, and key considerations for successful implementation.;Patil;Perspect Clin Res,2016
3. Expanded access of investigational drugs: the experience of the Center of Drug Evaluation and Research over a 10-year period.;Jarow;Ther Innov Regul Sci,2016
4. Expanded Access Programme: looking for a common definition.;Iudicello;Trials,2016
5. Ethically allocating COVID-19 drugs via pre-approval access and emergency use authorization.;Webb;Am J Bioeth,2020
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A Qualitative Interview Study on Expanded Access Clinical Trials for Compassionate Use in Japan;Patient Preference and Adherence;2024-07
2. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridioides difficile infection and other potential indications: second edition of joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines;Journal of Hospital Infection;2024-06
3. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridioides difficile infection and other potential indications: second edition of joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines;Gut;2024-04-12
4. Global Risdiplam Compassionate Use Program for Patients with Type 1 or 2 Spinal Muscular Atrophy;Clinical Therapeutics;2024-04
5. Ruxolitinib in patients with graft versus host disease (GvHD): findings from a compassionate use program;Bone Marrow Transplantation;2024-02-15
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3